Oppenheimer analyst Jay Olson assigned a Buy rating to Crispr Therapeutics AG (CRSP) yesterday and set a price target of $189.00. The company’s shares closed last Friday at $127.00.
According to TipRanks.com, Olson is a 4-star analyst with an average return of 11.5% and a 50.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $151.13 average price target, implying a 17.0% upside from current levels. In a report issued on June 3, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $539K and GAAP net loss of $113 million. In comparison, last year the company earned revenue of $157K and had a GAAP net loss of $69.73 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
